Last updated: 24 May 2024 at 5:00pm EST

Vickie S. Reed Net Worth




The estimated Net Worth of Vickie S Reed is at least $1.29 Million dollars as of 14 January 2022. Ms Reed owns over 533 units of Mirati Therapeutics Inc stock worth over $902,160 and over the last 5 years she sold MRTX stock worth over $388,429.

Ms Reed MRTX stock SEC Form 4 insiders trading

Ms has made over 4 trades of the Mirati Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 533 units of MRTX stock worth $64,216 on 14 January 2022.

The largest trade she's ever made was selling 779 units of Mirati Therapeutics Inc stock on 6 January 2021 worth over $165,327. On average, Ms trades about 201 units every 31 days since 2020. As of 14 January 2022 she still owns at least 15,369 units of Mirati Therapeutics Inc stock.

You can see the complete history of Ms Reed stock trades at the bottom of the page.





Ms. Vickie S. Reed biography

Vickie S. Reed is the Sr. VP & Chief Accounting Officer at Mirati Therapeutics Inc.



How old is Ms Reed?

Ms Reed is 59, she's been the Sr. VP & Chief Accounting Officer of Mirati Therapeutics Inc since . There are 8 older and 10 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.

What's Ms Reed's mailing address?

Vickie's mailing address filed with the SEC is C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH, CA, 92075.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., and Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.



What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.



What does Mirati Therapeutics Inc's logo look like?

Mirati Therapeutics Inc logo

Complete history of Ms Reed stock trades at Adamis Pharmaceuticals Corp, Evoke Pharma Inc, and Mirati Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
14 Jan 2022 Vickie S Reed
SVP and Chief Accounting Officer
Sale 533 $120.48 $64,216
14 Jan 2022
15,369
7 Jan 2022 Vickie S Reed
SVP and Chief Accounting Officer
Sale 345 $135.94 $46,899
7 Jan 2022
10,525
4 Jan 2022 Vickie S Reed
SVP and Chief Accounting Officer
Sale 758 $147.74 $111,987
4 Jan 2022
10,870
6 Jan 2021 Vickie S Reed
SVP and Chief Accounting Officer
Sale 779 $212.23 $165,327
6 Jan 2021
7,471


Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: